The V-LAP device allows medical teams to monitor the pressure inside a patient’s heart in real time, allowing them to make better decisions about the patient’s medications and improving outcomes.

At Vanderbilt University Hospital, there are approximately 75,000 adult emergency department visits a year, and approximately 20% of all ED patients receive a cardiac troponin test as part of their initial evaluation. The new cardiac troponin test is more precise and provides results faster.

Patients with a form of heart failure called HFpEF may breathe normally at rest but quickly become breathless with physical activity. The study will test an atrial shunt to relieve high pressure in the heart.

A multicenter study led by Vanderbilt University Medical Center and Lipscomb University College of Pharmacy in Nashville has identified a potential new treatment for acute heart failure, a leading cause of hospitalization and death.

New implantable device helps heart failure patients monitor crucial health indicators remotely, reducing the need for hospital visits.

A study co-led by Vanderbilt researchers found heart failure risk is 19% higher for adults living in rural areas of the U.S., as compared to urban areas, and 34% higher for Black men living in rural areas.

Vanderbilt researchers have discovered that a genetic predisposition to elevated body mass index increases the risk of diastolic dysfunction — a cardiac condition that can lead to heart failure.